Drug
GSK1278863 clinical trials
Also written GSK1278863 and Daprodustat.
- studies test it
- 34
- open now
- 1
- in phase 3
- 9
- first study started
- 2010
Keep track of what changes. Save the GSK1278863 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
34 studies that test it; most in 2013 (5)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 12
- Phase 3
- 9
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 33 · Other 1
GlaxoSmithKline (32) · USRC Kidney Research (1) · Qilu Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Erythropoietin (1) · Pioglitazone (1) · Rosuvastatin (1) · Trimethoprim (1) · Gemfibrozil (1)
Studies
Open first, then newest update. How each study uses GSK1278863 is read from its arms, and is right about nine times in ten.
Testing it · 34
- A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)Not yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07300111Written as Daprodustat
- Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With AnemiaTerminatedPhase 2GlaxoSmithKlineNCT02075463Written as GSK1278863
- Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)CompletedPhase 3GlaxoSmithKlineNCT05682326Written as Daprodustat
- Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy ParticipantsCompletedPhase 1GlaxoSmithKlineNCT04640311Written as Daprodustat
- A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney DiseaseCompletedPhase 4USRC Kidney ResearchNCT05951192Written as Daprodustat
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)CompletedPhase 3GlaxoSmithKlineNCT02876835Written as Daprodustat
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)CompletedPhase 3GlaxoSmithKlineNCT03409107Written as Daprodustat (GSK1278863)
- Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)CompletedPhase 2GlaxoSmithKlineNCT03457701Written as Daprodustat
- Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)TerminatedPhase 2GlaxoSmithKlineNCT03446612Written as Daprodustat
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)CompletedPhase 3GlaxoSmithKlineNCT02879305Written as Daprodustat
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)CompletedPhase 3GlaxoSmithKlineNCT03029208Written as Daprodustat
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)CompletedPhase 3GlaxoSmithKlineNCT03400033Written as Daprodustat tablets
- Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)CompletedPhase 2GlaxoSmithKlineNCT03029247Written as Daprodustat
- Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal AnemiaCompletedPhase 3GlaxoSmithKlineNCT02791763Written as 6 mg GSK1278863 tablet
- Daprodustat Bioequivalence and Food Effect StudyCompletedPhase 1GlaxoSmithKlineNCT03493386Written as Daprodustat 2 mg tablet
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating AgentCompletedPhase 2GlaxoSmithKlineNCT02689206Written as GSK1278863
- Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating AgentsCompletedPhase 3GlaxoSmithKlineNCT02829320Written as GSK1278863
- Absorption and Elimination of Radiolabeled DaprodustatCompletedPhase 1GlaxoSmithKlineNCT03239522Written as [14C]-GSK1278863 oral solution
- Daprodustat Hepatic Impairment StudyCompletedPhase 1GlaxoSmithKlineNCT03223337Written as Daprodustat (GSK1278863)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863CompletedPhase 1GlaxoSmithKlineNCT01831804Written as GSK1278863
See all 34 studies that test GSK1278863 →
As the comparator · 1 — what is tested is compared with GSK1278863
Codes
What other systems call GSK1278863 · ClinicalTrials.gg INT000270
- MeSH (NLM) C000599718GSK1278863One source NLM
- UNII (FDA) JVR38ZM64BDAPRODUSTATConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599718 | GSK1278863 | One source NLM |
| UNII (FDA) | JVR38ZM64B | DAPRODUSTAT | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.